Medical Imaging Convention [rescheduled] Sep 15, 2021 - Sep 16, 2021 — National Exhibition Centre, Birmingham, England
2021 SINAPSE ASM Sep 16, 2021 - Sep 17, 2021 — Technology & Innovation Centre, University of Strathclyde, 99 George Street, Glasgow
Total Body PET 2021 conference [rescheduled] Sep 22, 2021 - Sep 24, 2021 — Virtual Meeting (online)
PET is Wonderful Annual Meeting 2021 Oct 26, 2021 12:00 AM — Virtual Meeting (online)

eLearning

SINAPSE experts from around Scotland have developed ten online modules designed to explain medical imaging. They are freely available and are intended for non-specialists.


Edinburgh Imaging Academy at the University of Edinburgh offers the following online programmes through a virtual learning environment:

Neuroimaging for Research MSc/Dip/Cert

Imaging MSc/Dip/Cert

PET-MR Principles & Applications Cert

Applied Medical Image Analysis Cert

Online Short Courses

alpha 4 beta 2 nicotinic receptor status in Alzheimer's disease using I-123-5IA-85380 single-photon-emission computed tomography

Author(s): J. T. O'Brien, S. J. Colloby, S. Pakrasi, E. K. Perry, S. L. Pimlott, D. J. Wyper, I. G. McKeith, E. D. Williams

Abstract:
Background: Loss of the alpha 4 beta 2 nicotinic receptor subtype is found at autopsy in Alzheimer's disease. Objective: To investigate in vivo changes in this receptor using single-photon-emission CT (SPECT) with I-123-5-iodo-3-[2(S)-2-azetidinylmethoxy] pyridine (5IA-85380), a novel nicotinic acetylcholine receptor ligand which binds predominantly to the a4b2 receptor. Methods: 32 non-smoking subjects (16 with Alzheimer's disease and 16 normal elderly controls) underwent I-123-5IA-85380 and perfusion (Tc-99m-hexamethylenepropyleneamine oxime (HMPAO)) SPECT scanning. Region of interest analysis was performed with cerebellar normalisation. Results: Significant bilateral reductions in nicotinic receptor binding were identified in frontal (left, p = 0.004; right, p = 0.002), striatal (left, p = 0.004; right, p = 0.003), right medial temporal (p = 0.04) and pons (p < 0.001) in patients with AD compared to controls. There were no significant correlations with clinical or cognitive measures. The pattern of nicotinic binding significantly differed from that of perfusion in both patients with AD and controls. Both I-123-5IA-85380 and 99mTc-HMPAO SPECT imaging demonstrated similar diagnostic performance in correctly classifying controls and patients with AD. Conclusion: Using I-123-5IA-85380 SPECT we found changes consistent with significant reductions in the nicotinic alpha 4 beta 2 receptor in cortical and striatal brain regions. This method could facilitate diagnosis and may be useful for monitoring progression of the disease and response to treatment in patients with AD and related diseases.

Full version: Available here

Click the link to go to an external website with the full version of the paper


ISBN: 0022-3050
Publication Year: 2007
Periodical: Journal of Neurology Neurosurgery and Psychiatry
Periodical Number: 4
Volume: 78
Pages: 356-361
Author Address: